February 26, 2020 / 2:47 PM / a month ago

BRIEF-Arcus Biosciences And Taiho Pharmaceutical Jointly Announce Taiho's Exercise Of Its Option For An Exclusive License To Zimberelimab

Feb 26 (Reuters) - Arcus Biosciences Inc:

* ARCUS BIOSCIENCES AND TAIHO PHARMACEUTICAL CO., LTD. JOINTLY ANNOUNCE TAIHO’S EXERCISE OF ITS OPTION FOR AN EXCLUSIVE LICENSE TO ZIMBERELIMAB (AB122) FOR ITS TERRITORIES IN JAPAN AND OTHER ASIAN COUNTRIES

* ARCUS BIOSCIENCES - ELIGIBLE TO GET ADDITIONAL CLINICAL, REGULATORY & COMMERCIALIZATION MILESTONES OF UP TO $275 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below